secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2025-05-27T23:59:59+00:00
Accession:  0001789769-25-000059
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio and ImmuneOnco report Phase 2 NSCLC trial of IMM2510 on track; initial data expected 2H 2025
--------------------------------------------------------------------------------

- Phase 2 trial of IMM2510 + chemo in first-line NSCLC in China to complete enrollment of ~60 patients by Q3 2025.
- Initial safety and efficacy results from the Phase 2 trial anticipated in second half of 2025.
- ORR of 23.1% observed in Phase 1 monotherapy for relapsed/refractory NSCLC (efficacy evaluable n=13).
- US Phase 1b/2 monotherapy dose optimization trial of IMM2510 expected to start before end of 2025, subject to regulatory approvals.
- Phase 3 trial of IMM2510 + chemo in first-line NSCLC anticipated to start in mid-2026 in China, pending regulatory discussions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976925000059/0001789769-25-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976925000059/til-20250522.htm
  HTML page:      https://secwatch.observer/filing/0001789769-25-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer